{"id":"NCT03721978","sponsor":"Inovio Pharmaceuticals","briefTitle":"REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)","officialTitle":"A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-28","primaryCompletion":"2022-08-23","completion":"2022-09-15","firstPosted":"2018-10-26","resultsPosted":"2024-10-17","lastUpdate":"2024-10-17"},"enrollment":203,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cervical Dysplasia","Cervical High Grade Squamous Intraepithelial Lesion","HSIL"],"interventions":[{"type":"BIOLOGICAL","name":"VGX-3100","otherNames":[]},{"type":"BIOLOGICAL","name":"Matched Placebo","otherNames":[]},{"type":"DEVICE","name":"CELLECTRA™-5PSP","otherNames":[]}],"arms":[{"label":"VGX-3100 + EP","type":"EXPERIMENTAL"},{"label":"Matched Placebo + EP","type":"PLACEBO_COMPARATOR"}],"summary":"HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed high-grade squamous intraepithelial lesions (HSIL) (cervical intraepithelial neoplasia grade 2 \\[CIN2\\] or grade 3 \\[CIN3\\]) of the cervix, associated with human papillomavirus (HPV-16) and/or HPV-18.","primaryOutcome":{"measure":"Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples","timeFrame":"At Week 36","effectByArm":[{"arm":"VGX-3100 + EP","deltaMin":28.6,"sd":null},{"arm":"Matched Placebo + EP","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.115"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":53,"countries":["United States","Argentina","Brazil","Estonia","Finland","Lithuania","Poland","Puerto Rico","South Africa","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":134},"commonTop":["Injection site pain","Headache","Fatigue","Myalgia","Injection site swelling"]}}